Genprex (GNPX) Operating Income (2016 - 2025)
Genprex (GNPX) posted quarterly Operating Income of -$667838.0 for Q1 2025, up 88.86% year-over-year from -$353609.2 in Q1 2024, and up 84.6% quarter-over-quarter from -$4.3 million in Q4 2024.
Genprex (GNPX) Operating Income (2016 - 2025) Analysis & Trends
Genprex's Operating Income history runs 10 years deep, the most recent figure standing at -$667838.0 for Q1 2025.
- In Q1 2025, Operating Income rose 88.86% year-over-year to -$667838.0; the TTM figure through Mar 2025 stood at -$15.8 million (up 42.98% YoY), while the FY2025 annual figure was -$15.5 million, up 26.72% from the prior year.
- Operating Income for Q1 2025 stood at -$667838.0, up from -$4.3 million in the prior quarter.
- The five-year high for Operating Income was -$667838.0 in Q1 2025, with the low at -$9.3 million in Q1 2023.
- The 5-year median for Operating Income is -$6.0 million (2023), against an average of -$5.7 million.
- The sharpest annual moves came in 2022 and 2025: Operating Income slumped 79.43% in 2022, then soared 88.86% in 2025.
- Genprex's Operating Income stood at -$6.8 million in 2021, then grew by 2.56% to -$6.6 million in 2022, then gained by 9.29% to -$6.0 million in 2023, then increased by 27.35% to -$4.3 million in 2024, then surged by 84.6% to -$667838.0 in 2025.
- Business Quant data shows GNPX's Operating Income at -$667838.0 in Q1 2025, -$4.3 million in Q4 2024, and -$4.3 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Genprex | 1.89 Mn | -13.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -667,838.00 |
| Dec 31, 2024 | -4.34 Mn |
| Sep 30, 2024 | -4.32 Mn |
| Jun 30, 2024 | -6.52 Mn |
| Mar 31, 2024 | -6.00 Mn |
| Dec 31, 2023 | -5.97 Mn |
| Sep 30, 2023 | -7.79 Mn |
| Jun 30, 2023 | -8.04 Mn |
| Mar 31, 2023 | -9.26 Mn |
| Dec 31, 2022 | -6.58 Mn |
| Sep 30, 2022 | -6.17 Mn |
| Jun 30, 2022 | -5.77 Mn |
| Mar 31, 2022 | -5.31 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -3.44 Mn |
| Jun 30, 2021 | -3.99 Mn |
| Mar 31, 2021 | -5.31 Mn |
| Dec 31, 2020 | -5.23 Mn |
| Sep 30, 2020 | -2.78 Mn |
| Jun 30, 2020 | -4.38 Mn |